Ovarian Cancer: The Impact of PARP Inhibitor Therapy on Resource Utilization and Challenges Affecting Patient Access

Ovarian Cancer: The Impact of PARP Inhibitor Therapy on Resource Utilization and Challenges Affecting Patient Access

Faculty Presenters

Jason Bergsbaken, PharmD, BCOP
Pharmacy Coordinator, Regional Oncology Services
UW Health
Madison, Wisconsin

Tim Peterson, PharmD, BCOP
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Rebecca Tombleson, PharmD, BCOP
Director of Pharmacy Operations
Oncology Analytics, Inc.
Tampa, Florida

Medical Writer

Debra Gordon, MS
President
GordonSquared, Inc
Highland Park, Illinois
 
Program Description
Patients with ovarian cancer with advanced disease or residual disease or those who undergo multiple rounds of platinum-based chemotherapy are at risk for decreased survival and increased disease resistance. The incorporation of PARP inhibitors into the treatment paradigm of ovarian cancer represents an opportunity to meet unmet needs in the treatment and maintenance of this disease. While clinical studies have demonstrated positive outcomes, economic analyses have presented considerable variations in the cost-effectiveness of PARP inhibitors across cancer types, including ovarian cancer. Managed care professionals and pharmacists must navigate a delicate balance between access to and utilization of PARP inhibitors in ovarian cancer. The financial implications of the use of oral oncolytics remains a significant challenge, limiting affordability and patient access. This discussion will address care delivery and payment models between payers, health systems, and pharmacies, and steps these entities can take to facilitate patient access to oral oncolytics such as PARP inhibitors.

Target Audience: Managed care and oncology pharmacists
Type of Activity: Application
Release date: April 26, 2021
Expiration date: April 26, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Identify emerging trends in the clinical use of PARP inhibitors for the treatment of ovarian cancer
• Explain how the recent trends in use of PARP inhibitors will impact the cost of caring for patients with ovarian cancer
• Explore challenges affecting patient access to oral oncolytics such as PARP inhibitors

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-165-H01-P. The activity is available for CE credit through April 26, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Jason Bergsbaken, PharmD, BCOP; Tim Peterson, PharmD, BCOP; and Rebecca Tombleson, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.

Medical Writing Support

Debra Gordon, MS, has the following relevant financial relationships with commercial interests
to disclose:

• Stockholder: Merck Sharp & Dohme Corp, AbbVie
• Spouse: Employed by AbbVie

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms